TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00686270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apricitabine
Description: Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.
Study: NCT02959749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: 80 mg oral daily; until disease progression, intolerable toxicities, or patient death.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: docetaxel, bevacizumab
Description: Docetaxel and bevacizumab are common used in third line therapy in non-small cell lung cancer if not used before. Docetaxel (75 mg/m2) intravenous infusion on day 1 and bevacizumab (7.5 mg/kg) on day 1 every 21days a cycle, until disease progression, intolerable toxicities, or patient death.
Study: NCT03512639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Homeopathic Medication
Description: Homeopathic medication (Arnica montana and the Bellis perennis) were given to women in the study group following mastectomy and reconstruction to reduce post operative seroma

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo was given to women in the control group following mastectomy and reconstruction to reduce post operative seroma
Study: NCT03027375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qishen Granules
Description: The QSG are manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China), a company that has obtained Chinese Good Manufacturing Practice for Pharmaceutical Products certification. All the ingredients have been approved by the Chinese Ministry of Food and Drug Safety. 13.6 grams (dry weight) of granules consist of six herbs: Astragalus membranaceus (Fisch.) Bge. var. Mongolicus (Bge.) Hsiao (6g), Salvia miltiorrhiza Bge. (1.5g), Lonicera japonica Thunb. (2g), Scrophularia ningpoensis Hemsl. (2g), Aconitum carmichaeli Debx. (0.9g), and Glycyrrhiza uralensis Fisch. (1.2g).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China) as well, following the Specification for processing Chinese medicine in Beijing. The placebo granules are similar in appearance, taste, and scent to the Qishen granules.
Study: NCT02194036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Learning Oriented Physiotherapy
Description: Clinical practice based on a new understanding of the neurobiological basis for the interaction between body and mind, the foundation of learning and what is needed to bring about change of behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Widely Recognized Psychiatric Treatment
Description: Standard recognized psychiatric treatment tailored to individual needs.
Study: NCT00587392

Intervention type: DEVICE
Intervention: NDO Full-thickness Plicator
Description: The NDO Full-thickness Plicator intervention was performed as part of the original open-label Plicator study as previously reported. This intervention did not take place as part of this long-term follow-up data collection study.
Study: NCT00783068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lipopolysaccharide E. Coli 113:H 10:K negative
Description: Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lipopolysaccharide E. Coli 113:H 10:K negative
Description: Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.
Study: NCT01487343

Intervention type: BEHAVIORAL
Intervention: questionnaire and interview
Description: Interviews will be conducted with the first 10 participants who agree to be interviewed (or until data saturation is reached). Self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions. Data will be collected approximately 2 weeks - 6 months (2 - 24 weeks) after being prescribed capecitabine.
Study: NCT01910363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A2NTX
Description: Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX
Description: Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
Study: NCT01815970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation
Description: 8 weeks of Pulmonary Rehabilitation including exercise and COPD related education.
Study: NCT04592302

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: 2-4 weeks before surgery a blood draw will be taken to test for nicotine levels in the body

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Draw
Description: 2-4 weeks before surgery a blood draw will be taken to test for nicotine levels in the body
Study: NCT02046577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Cholecalciferol administration

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Cholecalciferol administration
Study: NCT04087278

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red Raspberry Ellagitannin Extract
Description: Purified red raspberries ellagitannins extract 560 mg (4 capsules/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red Raspberry Ellagitannin Extract
Description: Purified red raspberries ellagitannins extract 560 mg (4 capsules/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Red Raspberry Ellagitannin Extract
Description: Purified red raspberries ellagitannins extract 560 mg (4 capsules/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Placebo treatment matching intervention (no ellagitannin) 560 mg (4 capsules/day)
Study: NCT01483833

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iferanserin
Description: Iferanserin 0.5% ointment applied intra-anally twice daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo ointment applied intra-anally twice daily for 14 days
Study: NCT01106820

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised progressive resistance training
Description: Supervised progressive resistance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supervised progressive muscle relaxation training (Jacobsen method)
Description: Supervised progressive muscle relaxation training (Jacobsen method)
Study: NCT02681250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titanium-zirconium
Description: Titanium-zirconium implants will be installed according to the protocol earlier described in the detailed description.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Titanium
Description: Titanium implants will be installed according to the protocol earlier described in the detailed description.
Study: NCT03057314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amorphous Calcium Carbonate
Description: Subjects will be administered with:~1. ACC tablets, containing 200 mg elemental calcium~2. 1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension
Study: NCT04195581

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: Subjects were randomized to wear each lens and solution combination for a month.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: Subjects were randomized to wear each lens and solution combination for a month.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: comfilcon A
Description: Subjects were randomized to wear each lens and solution combination for a month.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A
Description: Subjects were randomized to wear each lens and solution combination for a month.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A
Description: Subjects were randomized to wear each lens and solution combination for a month.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: fanfilcon A
Description: Subjects were randomized to wear each lens and solution combination for a month.
Study: NCT01584076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Oral Donepezil Daily~Initial Dosage: Donepezil 5 mg tablets will be used. 1/2 tablet (≈2.5 mg)/day for 8 to 17 year olds OR 1 tablet (5 mg)/day for ≥18 year olds.~Dosage Escalation: Donepezil may be increased by 1/2 tablet (≈2.5 mg)/day every 4 weeks if the amblyopic eye visual acuity has not improved by ≥5 letters or 1 logMAR line to a maximum dosage of 1 1/2 tablets (≈7.5 mg)/day for 8 to 17 year olds OR 2 tablets (10 mg)/day for ≥18 year olds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patching
Description: Patching: 2 hours of daily patching will also be prescribed for 8 to 17 year olds only.
Study: NCT03623581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GB226
Description: 3mg/kg treat every 2 weeks
Study: NCT01883479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Telephone-based intervention designed to increase exercise among postpartum women.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness/Support
Description: Telephone-based intervention designed to provide support to postpartum women.
Study: NCT00457873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline in 5% dextrose (intravenous)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.45% saline in 5% dextrose (intravenous)
Study: NCT02367066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AR-C165395XX
Description: Oral dose of AR-C165395XX (tablets)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dose of placebo for AR-C165395XX (tablets)
Study: NCT04616391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insulin pump Medtronic 780G
Description: Patients from the AHCL group will use the MiniMed 780G AHCL system. This system is already CE-marked.~The AHCL system will be initiated first in Manual Mode (i.e. without AHCL control) with suspend before low feature (Visit 1).~The AHCL system will be initiated in Auto Mode (i.e. with AHCL control) at Visit 2 with the settings in the below table. The Insulin to Carb ratio (ICR) and the Active Insulin Time (AIT) may be adjusted by the physician during the study. The glucose target may not be adjusted, unless in case of safety concerns. The patients may not adjust system settings without consulting with the physician.~At each visit, the AHCL system data will be downloaded and reviewed by the physician. The patient interaction with the system will be evaluated, included sensor calibration, bolus management (before the meals and for corrections as needed), alarms and Auto Mode exits.
Study: NCT02877940

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ProSeal Laryngeal mask airway
Description: ProSeal was inserted in mechanically ventilated patients undergoing elective surgeries.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal Tube Suction- Disposable
Description: LTS-D was inserted in mechanically ventilated patients undergoing elective surgeries.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i-gel
Description: i-gel was inserted in mechanically ventilated patients undergoing elective surgeries.
Study: NCT03753009

Intervention type: PROCEDURE
Intervention: corneal cross-linking
Description: Epithelium-off CXL was performed according to the Siena (Dresden modified) protocol: 2% pilocarpine was instilled 30 minutes before treatment, the epithelium was removed using a blunt knife. An isotonic solution of riboflavin 0.1% and dextran 20% was instilled for 10 minutes of corneal soaking before starting UV-A irradiation. The solution was administered every 3 minutes for a total of 30 minutes of UV-A exposure at 3mW/cm2.~The iontophoresis device was filled with a hypoosmolar riboflavin 0.1% dextran-free solution enriched with ethylenediaminetetraacetic acid and trometamol. The device was then connected to a constant current generator initially set at 0.5 mA and increased to 1.0 mA to find out the individual tolerance. Iontophoresis was then performed for 5 minutes. The corneal device was then removed before performing UVA irradiation. During the irradiation phase (10 mW/cm2 for 9 minutes), good fluorescence was clearly detectable. The total treatment time was 14 minutes.

Intervention type: PROCEDURE
Intervention: corneal cross-linking
Description: Epithelium-off CXL was performed according to the Siena (Dresden modified) protocol: 2% pilocarpine was instilled 30 minutes before treatment, the epithelium was removed using a blunt knife. An isotonic solution of riboflavin 0.1% and dextran 20% was instilled for 10 minutes of corneal soaking before starting UV-A irradiation. The solution was administered every 3 minutes for a total of 30 minutes of UV-A exposure at 3mW/cm2.~The iontophoresis device was filled with a hypoosmolar riboflavin 0.1% dextran-free solution enriched with ethylenediaminetetraacetic acid and trometamol. The device was then connected to a constant current generator initially set at 0.5 mA and increased to 1.0 mA to find out the individual tolerance. Iontophoresis was then performed for 5 minutes. The corneal device was then removed before performing UVA irradiation. During the irradiation phase (10 mW/cm2 for 9 minutes), good fluorescence was clearly detectable. The total treatment time was 14 minutes.
Study: NCT00570817

Intervention type: OTHER
Group type: OTHER
Intervention: 12 hours of prehydration
Description: 12 hours of prehydration with an infusion rate of 150 ml/m2/hour with a solution of 5% glucose with 40 mmol sodium bicarbonate/L and 20 mmol potassium chloride/L.

Intervention type: OTHER
Group type: OTHER
Intervention: 12 hours of prehydration
Description: 12 hours of prehydration with an infusion rate of 150 ml/m2/hour with a solution of 5% glucose with 40 mmol sodium bicarbonate/L and 20 mmol potassium chloride/L.
Study: NCT01990092

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metanx
Description: Metanx is a prescription medical food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02936934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~200μg / kg of morphine + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration:24hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Interventions pre-specified to be administered to participants:~Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery~Intravenous infusion:~150μg / kg of oxycodone + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration: 24hours.
Study: NCT01768988

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Conventional treatment + placebo (during 90 days).~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~1. Paracetamol 1g/8h~2. Weak opioid (tramadol at maximal doses of 400 mg/24h)~3. Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS \< 3).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Treatment during 90 days with conventional treatment + pregabalin.~Pregabalin doses were reached until the maximal doses (300 mg/12h) depending on patient tolerability. An escalating dose scheme were desigened as follows, to avoid tolerability problems:~Week 1 75-0-75 Week 2 75-0-150 Week 3 150-0-150 Week 4 150-0-300 Week 5 300-0-300 (until the end of study)~Conventional treatment comprises a WHO step ladder approach and comprises in most cases:~1. Paracetamol 1g/8h~2. Weak opioid (tramadol at maximal doses of 400 mg/24h)~3. Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS \< 3).
Study: NCT00611338

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Skills-based Prevention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Skills-based Prevention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV Skills-based Prevention
Study: NCT01456689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGH447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGH447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: midazolam
Study: NCT02017379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoclopromide
Study: NCT00844207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed combination of Azithromycin and Chloroquine
Description: Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin and Chloroquine
Description: Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose.
Study: NCT03985345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intravaginal device (probe) EMY
Description: Free use of EMY and its mobile application for 10 minutes during 5 different days per week.
Study: NCT01237340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saizen®
Description: Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
Study: NCT01910116

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shinbaro
Description: GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The study medication and placebo were identical in appearance.
Study: NCT05330403

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: In this study, suspended moxibustion was performed by holding an ignited moxa stick at a certain distance (about 3-4 cm) over the skin surface, keeping the moxibustion Site warm without burning the skin.~In the heart meridian intervention group, moxibustion was applied over Site 4 (HT3) of the heart meridian.~In the lung meridian intervention group, moxibustion was performed over Site 1 (LU5) of the lung meridian.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Moxibustion
Description: In this study, suspended moxibustion was performed by holding an ignited moxa stick at a certain distance (about 3-4 cm) over the skin surface, keeping the moxibustion Site warm without burning the skin.~In the heart meridian intervention group, moxibustion was applied over Site 4 (HT3) of the heart meridian.~In the lung meridian intervention group, moxibustion was performed over Site 1 (LU5) of the lung meridian.
Study: NCT02742467

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril plus Amlodipine
Description: Group 1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril plus Amlodipine
Description: Group 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril plus Hydrochlorothiazide
Description: Group 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril plus Hydrochlorothiazide
Description: Group 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Hydrochlorothiazide
Description: Group 3

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine plus Hydrochlorothiazide
Description: Group 3
Study: NCT02024451

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radial shock wave
Description: radial shock wave: Treatment point is the origin attachment of upper trapezius at the external occipital protuberance. Radial shock wave therapy will be performed once per week, and will be continued for 3 weeks. Acetaminophen will be prescribed as rescue medication, and the amount given will be recorded at the end of the study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture is performed at Fenfchi (GB20) point over upper back by the same physiatrist to all patients.
Study: NCT01591317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Tablets orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Tablets orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: Tablets orally
Study: NCT02289352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brimonidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00685685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin 40 mg tablets
Description: 40 mg tablet administered after an overnight fast of at least 10 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin (Mevacor®) 40 mg Tablets
Description: 40 mg tablet administered after an overnight fast of at least 10 hours